Author Index Volume 53 (2016)
The issue number is given in front of the pagination
Aarsland, D. see Tajeddinn, W. (2) 621–630
Aarsland, D., see Brønnick, K. (4) 1277–1285
Aarsland, D., see Tajeddinn, W. (1) 349–361
Abdullah, M., H. Takase, M. Nunome, H. Enomoto, J.-i. Ito, J.-S. Gong and M. Michikawa, Amyloid-β Reduces Exosome Release from Astrocytes by Enhancing JNK Phosphorylation (4) 1433–1441
Abe, K., see Zhai, Y. (3) 893–905
Adams, H.H., see Chouraki, V. (3) 921–932
Adedokun, O.J., see Russu, A. (2) 535–546
Adiele, C.A., see Adiele, R.C. (4) 1257–1270
Adiele, R.C. and C.A. Adiele, Mitochondrial Regulatory Pathways in the Pathogenesis of Alzheimer’s Disease (4) 1257–1270
Aerts, T., see Vermeiren, Y. (3) 1079–1096
Aguayo, L.G., see Peters, C. (1) 197–207
Ahmed, M.S., see Tajeddinn, W. (1) 349–361
Ahmed, M.S., see Tajeddinn, W. (2) 621–630
Ahmed, R., see Dermody, N. (3) 801–816
Akoudad, S., M.E. Gurol, P. Fotiadis, P.J. Koudstaal, A. Hofman, M.A. Ikram, S.M. Greenberg and M.W. Vernooij, Cerebral Microbleeds and Cerebrovascular Reactivity in the General Population: The EDAN Study (2) 497–503
Al Rihani, S.B., see Qosa, H. (4) 1499–1516
Albani, D., see Biella, G. (3) 1193–1207
Allen, H.B., Alzheimer’s Disease: Assessing the Role of Spirochetes, Biofilms, the Immune System, and Amyloid-β with Regard to Potential Treatment and Prevention (4) 1271–1276
Allué, J.A., L. Sarasa, M. Izco, V. Pérez-Grijalba, N. Fandos, M. Pascual-Lucas, S. Ogueta, P. Pesini and M. Sarasa, Outstanding Phenotypic Differences in the Profile of Amyloid-β between Tg2576 and APPswe/PS1dE9 Transgenic Mouse Models of Alzheimer’s Disease (3) 773–785
Almeida, M.R., see Luis, E. (1) 303–313
Amariglio, R.E., see Hsu, D.C. (3) 1097–1105
Amen, D.G., K. Willeumier, B. Omalu, A. Newberg, C. Raghavendra and C.A. Raji, Perfusion Neuroimaging Abnormalities Alone Distinguish National Football League Players from a Healthy Population (1) 237–241
Amouyel, P., see Chouraki, V. (3) 921–932
Andersson, C.-H., O. Hansson, L. Minthon, N. Andreasen, K. Blennow, H. Zetterberg, I. Skoog, A. Wallin, S. Nilsson and P. Kettunen, A Genetic Variant of the Sortilin 1 Gene is Associated with Reduced Risk of Alzheimer’s Disease (4) 1353–1363
Andreasen, N., see Andersson, C.-H. (4) 1353–1363
Andrew, M.K., see Armstrong, J.J. (3) 1003–1013
Annweiler, C., see Landel, V. (2) 419–444
Antequera-Torres, M., see Marín-Muñoz, J. (1) 73–78
Antúnez-Almagro, C., see Marín-Muñoz, J. (1) 73–78
Araújo, L.F., S.S. Mirza, D. Bos, W.J. Niessen, S.M. Barreto, A. van der Lugt, M.W. Vernooij, A. Hofman, H. Tiemeier and M.A. Ikram, Association of Coffee Consumption with MRI Markers and Cognitive Function: A Population-Based Study (2) 451–461
Arcuti, S., see Sassi, C. (2) 475–485
Arendash, G.W., Review of the Evidence that Transcranial Electromagnetic Treatment will be a Safe and Effective Therapeutic Against Alzheimer’s Disease (3) 753–771
Arighi, A., see Galimberti, D. (2) 445–449
Armstrong, J.J., J. Godin, L.J. Launer, L.R. White, A. Mitnitski, K. Rockwood and M.K. Andrew, Changes in Frailty Predict Changes in Cognition in Older Men: The Honolulu-Asia Aging Study (3) 1003–1013
Arroyo, P., see Eugenín, J. (3) 857–873
Asahi, M., see Ueda, Y. (1) 315–325
Ash, E.L., see Yogev-Seligmann, G. (2) 517–533
Atanackovic, J., see Mohseni, H.K. (3) 933–942
Au, R., see Bangen, K.J. (4) 1553–1562
Aubert, I., see Maliszewska-Cyna, E. (1) 243–257
Ayers, E., see Callisaya, M.L. (3) 1043–1052
Back, J.H., see Roh, H.W. (2) 463–473
Bäckman, L., see Marseglia, A. (3) 1069–1078
Baek, J.-H., see Kang, S. (4) 1563–1576
Baez, S., see Pietto, M. (4) 1325–1340
Bailey, K.R., see Kantarci, K. (2) 547–556
Baldereschi, M., see Di Carlo, A. (2) 505–515
Balducci, C., see Stravalaci, M. (4) 1485–1497
Bálind, Á., see Kasza, Á. (2) 557–571
Ballina, L., see Perkins, M. (1) 95–106
Balogh, G., see Kasza, Á. (2) 557–571
Bamji-Mirza, M., Y. Li, D. Najem, Q.Y. Liu, D. Walker, L.-F. Lue, J. Stupak, K. Chan, J. Li, M. Ghani, Z. Yang, E. Rogaeva and W. Zhang, Genetic Variations in ABCA7 Can Increase Secreted Levels of Amyloid-β40 and Amyloid-β42 Peptides and ABCA7 Transcription in Cell Culture Models (3) 875–892
Bangen, K.J., J.J. Himali, A.S. Beiser, D.A. Nation, D.J. Libon, C.S. Fox, S. Seshadri, P.A. Wolf, A.C. McKee, R. Au and L. Delano-Wood, Interaction Between Midlife Blood Glucose and APOE Genotype Predicts Later Alzheimer’s Disease Pathology (4) 1553–1562
Barhum, Y., see Salomon-Zimri, S. (4) 1443–1458
Barkhof, F., see Vijverberg, E.G.B. (4) 1287–1297
Barreto, S.M., see Araújo, L.F. (2) 451–461
Barros, H., see Moreira, A. (1) 85–93
Barrows, R.J., see Paholpak, P. (1) 327–335
Barulli, M.R., see Sassi, C. (2) 475–485
Barzilai, N., see Callisaya, M.L. (3) 1043–1052
Batarseh, Y.S., see Qosa, H. (4) 1499–1516
Batlle, A., see Merino-Zamorano, C. (2) 677–691
Bayer, T.A., see Jakobsen, J.E. (4) 1617–1630
Beckett, T.L., see Lovell, M.A. (1) 273–287
Beeg, M., see Stravalaci, M. (4) 1485–1497
Behbahani, H., see Tajeddinn, W. (2) 621–630
Bei, B., see Cavuoto, M.G. (3) 943–953
Beiser, A.S., see Bangen, K.J. (4) 1553–1562
Beiser, A.S., see Camargo, E.C. (4) 1597–1608
Belger, M., see Happich, M. (1) 171–183
Bellenguez, C., see Chouraki, V. (3) 921–932
Bennett, D.A., see Chouraki, V. (3) 921–932
Ben-Sadoun, G., G. Sacco, V. Manera, J. Bourgeois, A. König, P. Foulon, B. Fosty, F. Bremond, F. d’Arripe-Longueville and P. Robert, Physical and Cognitive Stimulation Using an Exergame in Subjects with Normal Aging, Mild and Moderate Cognitive Impairment (4) 1299–1314
Ben-Zur, T., see Salomon-Zimri, S. (4) 1443–1458
Berg, D., see Glonnegger, H. (4) 1475–1484
Bernáth, S., see Kasza, Á. (2) 557–571
Bernocchi, O., see Biella, G. (3) 1193–1207
Berr, C., see Chouraki, V. (3) 921–932
Bertram, K., see Galimberti, D. (2) 445–449
Bester, J., see Pretorius, E. (4) 1237–1256
Beyle, A., see Glonnegger, H. (4) 1475–1484
Biasini, E., see Stravalaci, M. (4) 1485–1497
Bieberle, N.A., see Vidoni, E.D. (1) 161–170
Biella, G., F. Fusco, E. Nardo, O. Bernocchi, A. Colombo, S.F. Lichtenthaler, G. Forloni and D. Albani, Sirtuin 2 Inhibition Improves Cognitive Performance and Acts on Amyloid-β Protein Precursor Processing in Two Alzheimer’s Disease Mouse Models (3) 1193–1207
Birnbaum, H.G., see Happich, M. (1) 171–183
Bis, J.C., see Chouraki, V. (3) 921–932
Bisconti, A.V., see Venturelli, M. (4) 1631–1640
Black, J.R., see Vidoni, E.D. (1) 161–170
Blennow, K., see Andersson, C.-H. (4) 1353–1363
Blundell, K.L.I.M., see Kasza, Á. (2) 557–571
Bobkova, N., V. Vorobyov, N. Medvinskaya, I. Nesterova, O. Tatarnikova, P. Nekrasov, A. Samokhin, A. Deev, F. Sengpiel, D. Koroev and O. Volpina, Immunization Against Specific Fragments of Neurotrophin p75 Receptor Protects Forebrain Cholinergic Neurons in the Olfactory Bulbectomized Mice (1) 289–301
Boehm-Cagan, A., see Salomon-Zimri, S. (4) 1443–1458
Bolívar, J.C.C. and D.G. Saladie, Redefining Amnestic Mild Cognitive Impairment as an Early Form of Alzheimer’s Disease Based on Assessment of Memory Systems (2) 705–712
Borroni, B., see Luis, E. (1) 303–313
Bos, D., see Araújo, L.F. (2) 451–461
Bots, M.L., see van de Vorst, I.E. (1) 117–125
Bourgeois, J., see Ben-Sadoun, G. (4) 1299–1314
Bouter, Y., see Jakobsen, J.E. (4) 1617–1630
Boutoleau-Bretonnière, C., see Luis, E. (1) 303–313
Bovis, F., see Di Carlo, A. (2) 505–515
Bradley-Whitman, M., see Lovell, M.A. (1) 273–287
Bramanti, P., see Naro, A. (4) 1375–1388
Brashear, H.R., see Russu, A. (2) 535–546
Brasioli, A., see Venturelli, M. (4) 1631–1640
Breitve, M.H., see Brønnick, K. (4) 1277–1285
Bremond, F., see Ben-Sadoun, G. (4) 1299–1314
Brescia, V., see Sassi, C. (2) 475–485
Brix, B., see Vanderstichele, H.M.J. (3) 1121–1132
Brodtmann, A., H. Pemberton, D. Darby and A.P. Vogel, Diagnostic Distortions: A Case Report of Progressive Apraxia of Speech (1) 79–83
Broeckhoven, C.V., see Luis, E. (1) 303–313
Brønnick, K., M.H. Breitve, A. Rongve and D. Aarsland, Neurocognitive Deficits Distinguishing Mild Dementia with Lewy Bodies from Mild Alzheimer’s Disease are Associated with Parkinsonism (4) 1277–1285
Broster, L.S., see Yu, J. (2) 693–704
Brothers, H.M., see Penninkilampi, R. (4) 1395–1404
Bunai, T., see Oboshi, Y. (3) 817–830
Burns, J.M., see Vidoni, E.D. (1) 161–170
Buschke, H., see Mowrey, W.B. (4) 1585–1595
Bustin, J., see Pietto, M. (4) 1325–1340
Byun, S.H., see Mohseni, H.K. (3) 933–942
Cai, D., see El Gaamouch, F. (1) 15–29
Calabrò, R.S., see Naro, A. (4) 1375–1388
Callesen, H., see Jakobsen, J.E. (4) 1617–1630
Callisaya, M.L., E. Ayers, N. Barzilai, L. Ferrucci, J.M. Guralnik, R.B. Lipton, P. Otahal, V.K. Srikanth and J. Verghese, Motoric Cognitive Risk Syndrome and Falls Risk: A Multi-Center Study (3) 1043–1052
Calvo-Garrido, J., see Tajeddinn, W. (1) 349–361
Calvó-Perxas, L., see Garre-Olmo, J. (4) 1341–1351
Camacho, A., see González, H.M. (3) 955–965
Camargo, E.C., G. Weinstein, A.S. Beiser, Z.S. Tan, C. DeCarli, M. Kelly-Hayes, C. Kase, J.M. Murabito and S. Seshadri, Association of Physical Function with Clinical and Subclinical Brain Disease: The Framingham Offspring Study (4) 1597–1608
Campanari, M.-L., F. Navarrete, S.D. Ginsberg, J. Manzanares, J. Sáez-Valero and M.-S. García-Ayllón, Increased Expression of Readthrough Acetylcholinesterase Variants in the Brains of Alzheimer’s Disease Patients (3) 831–841
Cao, Y.-m. see Gao, H.-l. (3) 1173–1192
Capozzo, R., see Sassi, C. (2) 475–485
Caroppo, P., see Luis, E. (1) 303–313
Carr, D.R., see Paholpak, P. (1) 327–335
Cavuoto, M.G., B. Ong, K.E. Pike, C.L. Nicholas, B. Bei and G.J. Kinsella, Better Objective Sleep Quality in Older Adults with High Subjective Memory Decline (3) 943–953
Cè, E., see Venturelli, M. (4) 1631–1640
Cedazo-Minguez, A., see Tajeddinn, W. (1) 349–361
Cedazo-Minguez, A., see Tajeddinn, W. (2) 621–630
Cerff, B., see Glonnegger, H. (4) 1475–1484
Cermakova, P., see Lovas, J. (2) 631–638
Chan, K., see Bamji-Mirza, M. (3) 875–892
Chang, C.-W., see Lin, C.-Y. (3) 1053–1067
Chang, K.J., see Roh, H.W. (2) 463–473
Chavira, B., see Perkins, M. (1) 95–106
Chen, J., see Verma, N. (1) 259–272
Chen, K., see Malek-Ahmadi, M. (4) 1641–1652
Chen, K., see Zhang, J. (1) 185–195
Chen, K.-Y., see Tang, W. (1) 221–236
Chen, R.P.-Y., see Lin, C.-Y. (3) 1053–1067
Chen, S., see Deng, Y. (4) 1419–1432
Chen, Y., see Zhang, J. (1) 185–195
Chen, Z.-t., see Lin, C.-Y. (3) 1053–1067
Cheng, J., see Deng, Y. (4) 1419–1432
Cheng, J., see Tang, W. (1) 221–236
Cheng, X., see Wang, J. (3) 907–919
Cheng, Y.-S., see Lin, C.-Y. (3) 1053–1067
Chettle, D.R., see Mohseni, H.K. (3) 933–942
Chiesa, R., see Stravalaci, M. (4) 1485–1497
Cho, H.J., see Kang, S. (4) 1563–1576
Choi, S.H., see Chouraki, V. (3) 921–932
Choi, S.H., see Roh, H.W. (2) 463–473
Chouraki, V., C. Reitz, F. Maury, J.C. Bis, C. Bellenguez, L. Yu, J. Jakobsdottir, S. Mukherjee, H.H. Adams, S.H. Choi, E.B. Larson, A. Fitzpatrick, A.G. Uitterlinden, P.L. de Jager, A. Hofman, V. Gudnason, B. Vardarajan, C. Ibrahim-Verbaas, S.J. van der Lee, O. Lopez, J.-F. Dartigues, C. Berr, P. Amouyel, D.A. Bennett, C. van Duijn, A.L. DeStefano, L.J. Launer, M.A. Ikram, P.K. Crane, J.-C. Lambert, R. Mayeux and S. Seshadri for the International Genomics of Alzheimer’s Project, Evaluation of a Genetic Risk Score to Improve Risk Prediction for Alzheimer’s Disease (3) 921–932
Chow, M., see Verma, N. (1) 259–272
Christianson, T.J., see Krell-Roesch, J. (4) 1609–1616
Chung, Y.K., see Roh, H.W. (2) 463–473
Cioffi, S.M.G., see Galimberti, D. (2) 445–449
Coart, E., see Vanderstichele, H.M.J. (3) 1121–1132
Colombo, A., see Biella, G. (3) 1193–1207
Colom-Cadena, M., see Pickett, E.K. (3) 787–800
Colosimo, C., see Galimberti, D. (2) 445–449
Colpo, G.D., see Salem, H. (3) 1209–1230
Conde-Sala, J.L., see Perales, J. (3) 1133–1143
Cooper, S.K., see Vidoni, E.D. (1) 161–170
Copetti, M., see Sassi, C. (2) 475–485
Coppedè, F., see Grossi, E. (4) 1517–1522
Corallo, F., see Naro, A. (4) 1375–1388
Cornejo, F., see Eugenín, J. (3) 857–873
Corrigan, B., see Russu, A. (2) 535–546
Cowan, D., see Mohseni, H.K. (3) 933–942
Crane, P.K., see Chouraki, V. (3) 921–932
Crews, C., see Sassi, C. (2) 475–485
Cronin, H., see Feeney, J. (3) 1107–1114
Csoti, I., see Glonnegger, H. (4) 1475–1484
Cunha, G., see Luis, E. (1) 303–313
D’Agata, F., see Luis, E. (1) 303–313
d’Arripe-Longueville, F., see Ben-Sadoun, G. (4) 1299–1314
Darby, D., see Brodtmann, A. (1) 79–83
Dartigues, J.-F., see Chouraki, V. (3) 921–932
Dartigues, J.-F., see Dumurgier, J. (4) 1411–1418
David, R., V. Manera, R. Fabre, C. Pradier, P. Robert and K. Tifratene, Evolution of the Antidepressant Prescribing in Alzheimer’s Disease and Related Disorders Between 2010 and 2014: Results from the French National Database on Alzheimer’s Disease (BNA) (4) 1365–1373
Daviglus, M.L., see González, H.M. (3) 955–965
De Deyn, P.P., see Vermeiren, Y. (3) 1079–1096
de Jager, P.L., see Chouraki, V. (3) 921–932
de Jonge, R., see Willemse, E.A.J. (1) 107–116
De La Fuente, A., see Neugroschl, J. (1) 69–72
De Luca, R., see Naro, A. (4) 1375–1388
de Mendonça, A., see Moreira, A. (1) 85–93
De Roeck, E., see De Vos, A. (4) 1523–1538
De Salvo, S., see Naro, A. (4) 1375–1388
De Vos, A., H. Struyfs, D. Jacobs, E. Fransen, T. Klewansky, E. De Roeck, C. Robberecht, C. Van Broeckhoven, C. Duyckaerts, S. Engelborghs and E. Vanmechelen, The Cerebrospinal Fluid Neurogranin/BACE1 Ratio is a Potential Correlate of Cognitive Decline in Alzheimer’s Disease (4) 1523–1538
DeCarli, C., see Camargo, E.C. (4) 1597–1608
Deev, A., see Bobkova, N. (1) 289–301
del Valle, E., A. Navarro, E. Martínez-Pinilla, S. Torices and J. Tolivia, Apo J and Apo D: Complementary or Antagonistic Roles in Alzheimer’s Disease? (2) 639–650
Delano-Wood, L., see Bangen, K.J. (4) 1553–1562
Demeyer, L., see Vanderstichele, H.M.J. (3) 1121–1132
Deng, Y., J. Wei, J. Cheng, P. Zhong, Z. Xiong, A. Liu, L. Lin, S. Chen and Z. Yan, Partial Amelioration of Synaptic and Cognitive Deficits by Inhibiting Cofilin Dephosphorylation in an Animal Model of Alzheimer’s Disease (4) 1419–1432
Dermody, N., S. Wong, R. Ahmed, O. Piguet, J.R. Hodges and M. Irish, Uncovering the Neural Bases of Cognitive and Affective Empathy Deficits in Alzheimer’s Disease and the Behavioral-Variant of Frontotemporal Dementia (3) 801–816
Desai, U., see Happich, M. (1) 171–183
Despa, F., see Verma, N. (1) 259–272
DeStefano, A.L., see Chouraki, V. (3) 921–932
Di Carlo, A., M. Baldereschi, M. Lamassa, F. Bovis, M. Inzitari, V. Solfrizzi, F. Panza, L. Galluzzo, E. Scafato and D. Inzitari for the Italian Longitudinal Study on Aging Working Group, Daily Function as Predictor of Dementia in Cognitive Impairment, No Dementia (CIND) and Mild Cognitive Impairment (MCI): An 8-Year Follow-Up in the ILSA Study (2) 505–515
Di Iorio, R., see Rossini, P.M. (4) 1389–1393
Di Lorenzo, G., see Naro, A. (4) 1375–1388
Di Meco, A. and D. Praticò, MicroRNAs as Therapeutic Targets for Alzheimer’s Disease (2) 367–372
Diógenes, M.J., see Moreira, A. (1) 85–93
Diomede, L., see Stravalaci, M. (4) 1485–1497
Dols, A., see Vijverberg, E.G.B. (4) 1287–1297
Dong, Y., see Woody, S.K. (3) 1015–1031
Donovan, N.J., see Hsu, D.C. (3) 1097–1105
Dricot, L., see Hanseeuw, B. (2) 651–660
Dumurgier, J., J.-F. Dartigues, A. Gabelle, C. Paquet, M. Prevot, J. Hugon and C. Tzourio, Time Orientation and 10 Years Risk of Dementia in Elderly Adults: The Three-City Study (4) 1411–1418
Duong, Q.-V., see Qosa, H. (4) 1499–1516
Durieux-Lu, S., see Willemse, E.A.J. (1) 107–116
Duthie, M., see Jakobsen, J.E. (4) 1617–1630
Duyckaerts, C., see De Vos, A. (4) 1523–1538
Egeto, P., see Hird, M.A. (2) 713–729
El Gaamouch, F., P. Jing, J. Xia and D. Cai, Alzheimer’s Disease Risk Genes and Lipid Regulators (1) 15–29
Emilsson, L.S., see Farnsworth, B. (1) 209–219
Engelborghs, S., see De Vos, A. (4) 1523–1538
Enomoto, H., see Abdullah, M. (4) 1433–1441
Eriksdotter, M., see Garre-Olmo, J. (4) 1341–1351
Eriksdotter, M., see Lovas, J. (2) 631–638
Erkinjuntti, T., see Skrobot, O.A. (3) 981–989
Eslick, G.D., see Penninkilampi, R. (4) 1395–1404
Esposito, F., see Venturelli, M. (4) 1631–1640
Eudave, L., see Luis, E. (1) 303–313
Eugenín, J., A. Vecchiola, P. Murgas, P. Arroyo, F. Cornejo and R. von Bernhardi, Expression Pattern of Scavenger Receptors and Amyloid-β Phagocytosis of Astrocytes and Microglia in Culture are Modified by Acidosis: Implications for Alzheimer’s Disease (3) 857–873
Fabre, R., see David, R. (4) 1365–1373
Fandos, N., see Allué, J.A. (3) 773–785
Farnsworth, B., C. Peuckert, B. Zimmermann, E. Jazin, P. Kettunen and L.S. Emilsson, Gene Expression of Quaking in Sporadic Alzheimer’s Disease Patients is Both Upregulated and Related to Expression Levels of Genes Involved in Amyloid Plaque and Neurofibrillary Tangle Formation (1) 209–219
Feeney, J., G.M. Savva, C. O’Regan, B. King-Kallimanis, H. Cronin and R.A. Kenny, Measurement Error, Reliability, and Minimum Detectable Change in the Mini-Mental State Examination, Montreal Cognitive Assessment, and Color Trails Test among Community Living Middle-Aged and Older Adults (3) 1107–1114
Feistel, B., see Hofrichter, J. (3) 967–980
Feng, T., see Zhai, Y. (3) 893–905
Fenoglio, C., see Galimberti, D. (2) 445–449
Fereshtehnejad, S.-M., see Lovas, J. (2) 631–638
Fereshtehnejad, S.-M., see Tajeddinn, W. (2) 621–630
Fernández-de Retana, S., see Merino-Zamorano, C. (2) 677–691
Fernández-Pérez, E.J., see Peters, C. (1) 197–207
Féron, F., see Landel, V. (2) 419–444
Ferrucci, L., see Callisaya, M.L. (3) 1043–1052
Fields, J.A., see Kantarci, K. (2) 547–556
Fischer, C.E., see Hird, M.A. (2) 713–729
Fister, S., see Lovell, M.A. (1) 273–287
Fitzpatrick, A., see Chouraki, V. (3) 921–932
Flores, F., see Pietto, M. (4) 1325–1340
Forloni, G., see Biella, G. (3) 1193–1207
Forloni, G., see Stravalaci, M. (4) 1485–1497
Formica, A., see Galimberti, D. (2) 445–449
Fosty, B., see Ben-Sadoun, G. (4) 1299–1314
Fotiadis, P., see Akoudad, S. (2) 497–503
Foulon, P., see Ben-Sadoun, G. (4) 1299–1314
Fox, C.S., see Bangen, K.J. (4) 1553–1562
Francis, P., see Tajeddinn, W. (1) 349–361
Frank, Z., see Kasza, Á. (2) 557–571
Fransen, E., see De Vos, A. (4) 1523–1538
Fraser, P.E., see Jakobsen, J.E. (4) 1617–1630
Fratiglioni, L., see Marseglia, A. (3) 1069–1078
Fukui, Y., see Zhai, Y. (3) 893–905
Fülöp, F., see Kasza, Á. (2) 557–571
Funke, S.A., see Schuster, J. (1) 53–67
Fusco, F., see Biella, G. (3) 1193–1207
Gabelle, A., see Dumurgier, J. (4) 1411–1418
Gainotti, G., see Trojano, L. (1) 31–52
Galimberti, D., K. Bertram, A. Formica, C. Fenoglio, S.M.G. Cioffi, A. Arighi, E. Scarpini and C. Colosimo, Plasma Screening for Progranulin Mutations in Patients with Progressive Supranuclear Palsy and Corticobasal Syndromes (2) 445–449
Galimberti, D., see Luis, E. (1) 303–313
Galluzzo, L., see Di Carlo, A. (2) 505–515
Gao, H.-l., C. Li, H. Nabeka, T. Shimokawa, Z.-Y. Wang, Y.-m. Cao and S. Matsuda, An 18-mer Peptide Derived from Prosaposin Ameliorates the Effects of Aβ1–42 Neurotoxicity on Hippocampal Neurogenesis and Memory Deficit in Mice (3) 1173–1192
García, A.M., see Pietto, M. (4) 1325–1340
García-Ayllón, M.-S., see Campanari, M.-L. (3) 831–841
Garcia-Ptacek, S., see Garre-Olmo, J. (4) 1341–1351
Garre-Olmo, J., S. Garcia-Ptacek, L. Calvó-Perxas, O. Turró-Garriga, S. López-Pousa and M. Eriksdotter, Diagnosis of Dementia in the Specialist Setting: A Comparison Between the Swedish Dementia Registry (SveDem) and the Registry of Dementias of Girona (ReDeGi) (4) 1341–1351
Gascón-Bayarri, J., see Perales, J. (3) 1133–1143
Gazzina, S., see Luis, E. (1) 303–313
Geda, Y.E., see Krell-Roesch, J. (4) 1609–1616
Geng, Y., see Han, B. (4) 1539–1552
Ghani, M., see Bamji-Mirza, M. (3) 875–892
Gibbs, R., see Sassi, C. (2) 475–485
Giladi, N., see Yogev-Seligmann, G. (2) 517–533
Ginsberg, S.D., see Campanari, M.-L. (3) 831–841
Glat, M.J., see Salomon-Zimri, S. (4) 1443–1458
Gleason, C., see Kantarci, K. (2) 547–556
Glonnegger, H., A. Beyle, B. Cerff, S. Gräber, I. Csoti, D. Berg and I. Liepelt-Scarfone, The Multiple Object Test as a Performance Based Tool to Assess Cognitive Driven Activity of Daily Living Function in Parkinson’s Disease (4) 1475–1484
Gobbi, M., see Stravalaci, M. (4) 1485–1497
Godin, J., see Armstrong, J.J. (3) 1003–1013
Gómez-Tortosa, E., see Marín-Muñoz, J. (1) 73–78
Gong, J.-S., see Abdullah, M. (4) 1433–1441
González, H.M., W. Tarraf, N. Gouskova, C.J. Rodríguez, T. Rundek, E. Grober, A. Pirzada, P. González, P.L. Lutsey, A. Camacho, M.L. Daviglus, C. Wright and T.H. Mosley, Life’s Simple 7’s Cardiovascular Health Metrics are Associated with Hispanic/Latino Neurocognitive Function: HCHS/SOL Results (3) 955–965
González, P., see González, H.M. (3) 955–965
Gosselet, F., see Merino-Zamorano, C. (2) 677–691
Gossink, F., see Vijverberg, E.G.B. (4) 1287–1297
Goto, Y., see Yamasaki, T. (2) 661–676
Gouskova, N., see González, H.M. (3) 955–965
Gräber, S., see Glonnegger, H. (4) 1475–1484
Granata, G., see Rossini, P.M. (4) 1389–1393
Graves, R.S., see Vidoni, E.D. (1) 161–170
Greenberg, S.M., see Akoudad, S. (2) 497–503
Greer, C.S., see Vidoni, E.D. (1) 161–170
Grober, E., see González, H.M. (3) 955–965
Grossi, E., A. Stoccoro, P. Tannorella, L. Migliore and F. Coppedè, Artificial Neural Networks Link One-Carbon Metabolism to Gene-Promoter Methylation in Alzheimer’s Disease (4) 1517–1522
Grothe, M.J., see Peter, J. (3) 991–1001
Gudnason, V., see Chouraki, V. (3) 921–932
Guralnik, J.M., see Callisaya, M.L. (3) 1043–1052
Gurol, M.E., see Akoudad, S. (2) 497–503
Gustafson, D., see Wennberg, A.M.V. (2) 573–581
Habekost, M., see Jakobsen, J.E. (4) 1617–1630
Hagen, C.E., see Wennberg, A.M.V. (2) 573–581
Han, B., L. Yu, Y. Geng, L. Shen, H. Wang, Y. Wang, J. Wang and M. Wang, Chronic Stress Aggravates Cognitive Impairment and Suppresses Insulin Associated Signaling Pathway in APP/PS1 Mice (4) 1539–1552
Han, G., see Suh, S.W. (2) 731–741
Han, J.W., see Suh, S.W. (2) 731–741
Han, S.-H., see Kang, S. (4) 1563–1576
Han, Z.-M., see Tang, W. (1) 221–236
Hannequin, D., see Luis, E. (1) 303–313
Hanseeuw, B., L. Dricot, R. Lhommel, L. Quenon and A. Ivanoiu, Patients with Amyloid-Negative Mild Cognitive Impairment have Cortical Hypometabolism but the Hippocampus is Preserved (2) 651–660
Hansson, O., see Andersson, C.-H. (4) 1353–1363
Hansson, O., see Vanderstichele, H.M.J. (3) 1121–1132
Happich, M., N.Y. Kirson, U. Desai, S. King, H.G. Birnbaum, C. Reed, M. Belger, A. Lenox-Smith and D. Price, Excess Costs Associated with Possible Misdiagnosis of Alzheimer’s Disease Among Patients with Vascular Dementia in a UK CPRD Population (1) 171–183
Hascup, E.R., see Hascup, K.N. (1) 337–347
Hascup, K.N. and E.R. Hascup, Soluble Amyloid-β42 Stimulates Glutamate Release through Activation of the α7 Nicotinic Acetylcholine Receptor (1) 337–347
Hasegawa, Y., see Uekawa, K. (1) 127–133
Hawkins, K.M. and L.E. Sergio, Adults at Increased Alzheimer’s Disease Risk Display Cognitive-Motor Integration Impairment Associated with Changes in Resting-State Functional Connectivity: A Preliminary Study (3) 1161–1172
He, R., see Zhou, X. (3) 843–855
Hederstierna, C., see Idrizbegovic, E. (4) 1405–1410
Heimbach, B., see Peter, J. (3) 991–1001
Hendler, T., see Yogev-Seligmann, G. (2) 517–533
Hensley, K. and P. Kursula, Collapsin Response Mediator Protein-2 (CRMP2) is a Plausible Etiological Factor and Potential Therapeutic Target in Alzheimer’s Disease: Comparison and Contrast with Microtubule-Associated
Henstridge, C.M., see Pickett, E.K. (3) 787–800
Herbst, V., see Vanderstichele, H.M.J. (3) 1121–1132
Hernández-Guillamon, M., see Merino-Zamorano, C. (2) 677–691
Herrmann, A.G., see Pickett, E.K. (3) 787–800
Hersh, L.B., see Verma, N. (1) 259–272
Himali, J.J., see Bangen, K.J. (4) 1553–1562
Hird, M.A., P. Egeto, C.E. Fischer, G. Naglie and T.A. Schweizer, A Systematic Review and Meta-Analysis of On-Road Simulator and Cognitive Driving Assessment in Alzheimer’s Disease and Mild Cognitive Impairment (2) 713–729
Hishikawa, N., see Zhai, Y. (3) 893–905
Hodges, J.R., see Dermody, N. (3) 801–816
Hodges, J.R., see Langenhove, T.V. (3) 1033–1042
Hofman, A., see Akoudad, S. (2) 497–503
Hofman, A., see Araújo, L.F. (2) 451–461
Hofman, A., see Chouraki, V. (3) 921–932
Hofrichter, J., M. Krohn, T. Schumacher, C. Lange, B. Feistel, B. Walbroel and J. Pahnke, Sideritis spp. Extracts Enhance Memory and Learning in Alzheimer’s β-Amyloidosis Mouse Models and Aged C57Bl/6 Mice (3) 967–980
Höglund, K., see Tajeddinn, W. (1) 349–361
Höglund, K., see Tajeddinn, W. (2) 621–630
Holm, I.E., see Jakobsen, J.E. (4) 1617–1630
Hong, C.H., see Roh, H.W. (2) 463–473
Hong, H.S., see Kang, S. (4) 1563–1576
Hong, J.W., see Suh, S.W. (2) 731–741
Hooper, P.L., see Kasza, Á. (2) 557–571
Horie, S., see Yamasaki, T. (2) 661–676
Horváth, I., see Kasza, Á. (2) 557–571
Hou, C., see Li, X. (4) 1577–1584
Hsu, D.C., E.C. Mormino, A.P. Schultz, R.E. Amariglio, N.J. Donovan, D.M. Rentz, K.A. Johnson, R.A. Sperling and G.A. Marshall for the Harvard Aging Brain Study, Lower Late-Life Body-Mass Index is Associated with Higher Cortical Amyloid Burden in Clinically Normal Elderly (3) 1097–1105
Hu, C., see Russu, A. (2) 535–546
Hu, Y., see Zhou, X. (3) 843–855
Huang, E., see Li, W. (2) 393–402
Huang, J., see Zhou, X. (3) 843–855
Hugon, J., see Dumurgier, J. (4) 1411–1418
Hüll, M., see Peter, J. (3) 991–1001
Hunya, Á., see Kasza, Á. (2) 557–571
Hwang, D., see Kang, S. (4) 1563–1576
Hyman, B.T., see Pickett, E.K. (3) 787–800
Ibáñez, A., see Pietto, M. (4) 1325–1340
Ibrahimi, S., see Woody, S.K. (3) 1015–1031
Ibrahim-Verbaas, C., see Chouraki, V. (3) 921–932
Idrizbegovic, E., C. Hederstierna and U. Rosenhall, Mismatch Negativity and Ear Laterality in Alzheimer’s Disease and in Mild Cognitive Impairment (4) 1405–1410
Ii, Y., see Ueda, Y. (1) 315–325
Ikram, M.A., see Akoudad, S. (2) 497–503
Ikram, M.A., see Araújo, L.F. (2) 451–461
Ikram, M.A., see Chouraki, V. (3) 921–932
Inzitari, D., see Di Carlo, A. (2) 505–515
Inzitari, M., see Di Carlo, A. (2) 505–515
Irish, M., see Dermody, N. (3) 801–816
Ito, J.-i., see Abdullah, M. (4) 1433–1441
Ito, K., see Russu, A. (2) 535–546
Ivachtchenko, A.V., Y. Lavrovsky and I. Okun, AVN-101: A Multi-Target Drug Candidate for the Treatment of CNS Disorders (2) 583–620
Ivanoiu, A., see Hanseeuw, B. (2) 651–660
Izco, M., see Allué, J.A. (3) 773–785
Jack Jr, C., see Wennberg, A.M.V. (2) 573–581
Jack, C.R., see Krell-Roesch, J. (4) 1609–1616
Jack, Jr., C.R., see Kantarci, K. (2) 547–556
Jacobs, D., see De Vos, A. (4) 1523–1538
Jakobsdottir, J., see Chouraki, V. (3) 921–932
Jakobsen, J.E., M.G. Johansen, M. Schmidt, Y. Liu, R. Li, H. Callesen, M. Melnikova, M. Habekost, C. Matrone, Y. Bouter, T.A. Bayer, A.L. Nielsen, M. Duthie, P.E. Fraser, I.E. Holm and A.L. Jørgensen, Expression of the Alzheimer’s Disease Mutations AbPP695sw and PSEN1M146I in Double-Transgenic Göttingen Minipigs (4) 1617–1630
Janelidze, S., see Vanderstichele, H.M.J. (3) 1121–1132
Janssens, J., see Vermeiren, Y. (3) 1079–1096
Järemo, P., see Tajeddinn, W. (2) 621–630
Jazin, E., see Farnsworth, B. (1) 209–219
Jelic, V., see Tajeddinn, W. (2) 621–630
Jentarra, G., see Perkins, M. (1) 95–106
Jeong, H., see Kang, S. (4) 1563–1576
Jeong, H., see Suh, S.W. (2) 731–741
Jhoo, J.H., see Suh, S.W. (2) 731–741
Ji, Z., see Zhou, X. (3) 843–855
Jia, J., see Li, H. (2) 487–496
Jia, S., see Li, X. (4) 1577–1584
Jiang, Y., see Yu, J. (2) 693–704
Jiao, J., see Li, X. (4) 1577–1584
Jimenez, E., see Paholpak, P. (1) 327–335
Jing, P., see El Gaamouch, F. (1) 15–29
Johansen, M.G., see Jakobsen, J.E. (4) 1617–1630
Johansson, B., see Lovas, J. (2) 631–638
Johansson, K., see Lovas, J. (2) 631–638
Johnson, K.A., see Hsu, D.C. (3) 1097–1105
Jones, T.B., see Perkins, M. (1) 95–106
Jørgensen, A.L., see Jakobsen, J.E. (4) 1617–1630
Joshi, P., see Stravalaci, M. (4) 1485–1497
Kaddoumi, A., see Qosa, H. (4) 1499–1516
Kalaria, R., see Skrobot, O.A. (3) 981–989
Kaller, C.P., see Peter, J. (3) 991–1001
Kanba, S., see Yamasaki, T. (2) 661–676
Kang, D.R., see Roh, H.W. (2) 463–473
Kang, S., H. Jeong, J.-H. Baek, S.-J. Lee, S.-H. Han, H.J. Cho, H. Kim, H.S. Hong, Y.H. Kim, E.C. Yi, S.W. Seo, D.L. Na, D. Hwang and I. Mook-Jung, PiB-PET Imaging-Based Serum Proteome Profiles Predict Mild Cognitive Impairment and Alzheimer’s Disease (4) 1563–1576
Kantarci, K., V.J. Lowe, T.G. Lesnick, N. Tosakulwong, K.R. Bailey, J.A. Fields, L.T. Shuster, S.M. Zuk, M.L. Senjem, M.M. Mielke, C. Gleason, C.R. Jack, Jr., W.A. Rocca and V.M. Miller, Early Postmenopausal Transdermal 17β-Estradiol Therapy and Amyloid-β Deposition (2) 547–556
Karhunen, P., see Skrobot, O.A. (3) 981–989
Kase, C., see Camargo, E.C. (4) 1597–1608
Kasza, Á., Á. Hunya, Z. Frank, F. Fülöp, Z. Török, G. Balogh, M. Sántha, Á. Bálind, S. Bernáth, K.L.I.M. Blundell, C. Prodromou, I. Horváth, H.-J. Zeiler, P.L. Hooper, L. Vigh and B. Penke, Dihydropyridine Derivatives Modulate Heat Shock Responses and have a Neuroprotective Effect in a Transgenic Mouse Model of Alzheimer’s Disease (2) 557–571
Katz, M.J., see Mowrey, W.B. (4) 1585–1595
Kay, K.R., see Pickett, E.K. (3) 787–800
Kazokoglu, M.S., see Tajeddinn, W. (1) 349–361
Kehoe, P.G., see Skrobot, O.A. (3) 981–989
Kehr, J., see Tajeddinn, W. (1) 349–361
Kehr, J., see Tajeddinn, W. (2) 621–630
Kell, D.B., see Pretorius, E. (4) 1237–1256
Keller, J.N., see Qosa, H. (4) 1499–1516
Kelly-Hayes, M., see Camargo, E.C. (4) 1597–1608
Kenny, R.A., see Feeney, J. (3) 1107–1114
Kerssens, C.J., see Vijverberg, E.G.B. (4) 1287–1297
Kettunen, P., see Andersson, C.-H. (4) 1353–1363
Kettunen, P., see Farnsworth, B. (1) 209–219
Kida, H., see Ueda, Y. (1) 315–325
Kikuchi, M., see Oboshi, Y. (3) 817–830
Kim, B.-J., see Suh, S.W. (2) 731–741
Kim, D.K., see Roh, H.W. (2) 463–473
Kim, H., see Kang, S. (4) 1563–1576
Kim, J.L., see Suh, S.W. (2) 731–741
Kim, K., see Suh, S.W. (2) 731–741
Kim, K.W., see Suh, S.W. (2) 731–741
Kim, S.-G., see Suh, S.W. (2) 731–741
Kim, S.Y., see Roh, H.W. (2) 463–473
Kim, T., see Suh, S.W. (2) 731–741
Kim, T.H., see Suh, S.W. (2) 731–741
Kim, Y.H., see Kang, S. (4) 1563–1576
Kim-Mitsuyama, S., see Uekawa, K. (1) 127–133
King, S., see Happich, M. (1) 171–183
King-Kallimanis, B., see Feeney, J. (3) 1107–1114
Kinsella, G.J., see Cavuoto, M.G. (3) 943–953
Kira, J.-i., see Yamasaki, T. (2) 661–676
Kirson, N.Y., see Happich, M. (1) 171–183
Klewansky, T., see De Vos, A. (4) 1523–1538
Klivényi, P., see Szalárdy, L. (2) 373–392
Kloog, I., see Wilker, E.H. (4) 1315–1323
Klöppel, S., see Peter, J. (3) 991–1001
Knopman, D., see Wennberg, A.M.V. (2) 573–581
Knopman, D.S., see Krell-Roesch, J. (4) 1609–1616
Koek, H.L., see van de Vorst, I.E. (1) 117–125
Koffie, R.M., see Pickett, E.K. (3) 787–800
Koibuchi, N., see Uekawa, K. (1) 127–133
König, A., see Ben-Sadoun, G. (4) 1299–1314
Koroev, D., see Bobkova, N. (1) 289–301
Köstering, L., see Peter, J. (3) 991–1001
Koudstaal, P.J., see Akoudad, S. (2) 497–503
Koutrakis, P., see Wilker, E.H. (4) 1315–1323
Krell-Roesch, J., H. Ruider, V.J. Lowe, G.B. Stokin, A. Pink, R.O. Roberts, M.M. Mielke, D.S. Knopman, T.J. Christianson, M.M. Machulda, C.R. Jack, R.C. Petersen and Y.E. Geda, FDG-PET and Neuropsychiatric Symptoms among Cognitively Normal Elderly Persons: The Mayo Clinic Study of Aging (4) 1609–1616
Krohn, M., see Hofrichter, J. (3) 967–980
Krudop, W.A., see Vijverberg, E.G.B. (4) 1287–1297
Kursula, P., see Hensley, K. (1) 1–14
Kwak, K.P., see Suh, S.W. (2) 731–741
Lahr, J., see Peter, J. (3) 991–1001
Lamassa, M., see Di Carlo, A. (2) 505–515
Lambert, J.-C., see Chouraki, V. (3) 921–932
Landel, V., C. Annweiler, P. Millet, M. Morello and F. Féron, Vitamin D, Cognition and Alzheimer’s Disease: The Therapeutic Benefit is in the D-Tails (2) 419–444
Lange, C., see Hofrichter, J. (3) 967–980
Langenhove, T.V., C.E. Leyton, O. Piguet and J.R. Hodges, Comparing Longitudinal Behavior Changes in the Primary Progressive Aphasias (3) 1033–1042
Larson, E.B., see Chouraki, V. (3) 921–932
Lauer, E., see Peter, J. (3) 991–1001
Laukka, E.J., see Marseglia, A. (3) 1069–1078
Launer, L.J., see Armstrong, J.J. (3) 1003–1013
Launer, L.J., see Chouraki, V. (3) 921–932
Lavrovsky, Y., see Ivachtchenko, A.V. (2) 583–620
Le Ber, I., see Luis, E. (1) 303–313
Lee, C., Best Linear Unbiased Prediction of Individual Polygenic Susceptibility to Sporadic Vascular Dementia (3) 1115–1119
Lee, D.W., see Suh, S.W. (2) 731–741
Lee, D.Y., see Suh, S.W. (2) 731–741
Lee, J.-D., see Roh, H.W. (2) 463–473
Lee, J.J., see Suh, S.W. (2) 731–741
Lee, K.H., see Suh, S.W. (2) 731–741
Lee, K.S., see Roh, H.W. (2) 463–473
Lee, S.B., see Suh, S.W. (2) 731–741
Lee, S.-J., see Kang, S. (4) 1563–1576
Lee, Y., see Roh, H.W. (2) 463–473
Legaz-García, A., see Marín-Muñoz, J. (1) 73–78
Lemstra, A.W., see Staekenborg, S.S. (1) 135–142
Lenox-Smith, A., see Happich, M. (1) 171–183
Lerner, Y., see Yogev-Seligmann, G. (2) 517–533
Lesnick, T.G., see Kantarci, K. (2) 547–556
Leung, L., see Perkins, M. (1) 95–106
Leyton, C.E., see Langenhove, T.V. (3) 1033–1042
Lhommel, R., see Hanseeuw, B. (2) 651–660
Li, C., see Gao, H.-l. (3) 1173–1192
Li, H., J. Jia and Z. Yang, Mini-Mental State Examination in Elderly Chinese: A Population-Based Normative Study (2) 487–496
Li, J., see Bamji-Mirza, M. (3) 875–892
Li, J., see Yu, J. (2) 693–704
Li, R., see Jakobsen, J.E. (4) 1617–1630
Li, R., see Yu, J. (2) 693–704
Li, W. and E. Huang, An Update on Type 2 Diabetes Mellitus as a Risk Factor for Dementia (2) 393–402
Li, X., S. Jia, Z. Zhou, C. Hou, W. Zheng, P. Rong and J. Jiao, The Gesture Imitation in Alzheimer’s Disease Dementia and Amnestic Mild Cognitive Impairment (4) 1577–1584
Li, X., see Zhang, J. (1) 185–195
Li, Y., see Bamji-Mirza, M. (3) 875–892
Li, Z., see Zhang, J. (1) 185–195
Liao, T.-Y., see Lin, C.-Y. (3) 1053–1067
Libon, D.J., see Bangen, K.J. (4) 1553–1562
Lichtenthaler, S.F., see Biella, G. (3) 1193–1207
Liepelt-Scarfone, I., see Glonnegger, H. (4) 1475–1484
Li-Jung, L., see Paholpak, P. (1) 327–335
Lim, K.Y., see Roh, H.W. (2) 463–473
Limonta, E., see Venturelli, M. (4) 1631–1640
Lin, C., see Lin, C.-Y. (3) 1053–1067
Lin, C.-Y., Y.-S. Cheng, T.-Y. Liao, C. Lin, Z.-t. Chen, W.-I. Twu, C.-W. Chang, D. Tat-Wei Tan, R.-S. Liu, P.-h. Tu and R.P.-Y. Chen, Intranasal Administration of a Polyethylenimine-Conjugated Scavenger Peptide Reduces Amy-loid-β Accumulation in a Mouse Model of Alzheimer’s Disease (3) 1053–1067
Lin, L., see Deng, Y. (4) 1419–1432
Lipton, R.B., see Callisaya, M.L. (3) 1043–1052
Lipton, R.B., see Mowrey, W.B. (4) 1585–1595
Liraz, O., see Salomon-Zimri, S. (4) 1443–1458
Liu, A., see Deng, Y. (4) 1419–1432
Liu, E., see Russu, A. (2) 535–546
Liu, F., see Wang, J. (3) 907–919
Liu, G., see Wang, J. (3) 907–919
Liu, M., see Verma, N. (1) 259–272
Liu, Q.Y., see Bamji-Mirza, M. (3) 875–892
Liu, R.-S., see Lin, C.-Y. (3) 1053–1067
Liu, Y., see Jakobsen, J.E. (4) 1617–1630
Liu, Z., see Zhang, J. (1) 185–195
Lleo, A., see Pickett, E.K. (3) 787–800
Loewenstein, D.A., see Mowrey, W.B. (4) 1585–1595
Logroscino, G., see Sassi, C. (2) 475–485
Lopera, F., see Pietto, M. (4) 1325–1340
Lopez, O., see Chouraki, V. (3) 921–932
López-Motos, D., see Marín-Muñoz, J. (1) 73–78
López-Pousa, S., see Garre-Olmo, J. (4) 1341–1351
Lovas, J., S.-M. Fereshtehnejad, P. Cermakova, C. Lundberg, B. Johansson, K. Johansson, B. Winblad, M. Eriksdotter and D. Religa, Assessment and Reporting of Driving Fitness in Patients with Dementia in Clinical Practice: Data from SveDem, the Swedish Dementia Registry (2) 631–638
Love, S., see Skrobot, O.A. (3) 981–989
Lovell, M.A., B.C. Lynn, S. Fister, M. Bradley-Whitman, M.P. Murphy, T.L. Beckett and C.M. Norris, A Novel Small Molecule Modulator of Amyloid Pathology (1) 273–287
Lowe, V.J., see Kantarci, K. (2) 547–556
Lowe, V.J., see Krell-Roesch, J. (4) 1609–1616
Lu, M., see Russu, A. (2) 535–546
Lue, L.-F., see Bamji-Mirza, M. (3) 875–892
Luis, E., A. Ortiz, L. Eudave, S. Ortega-Cubero, B. Borroni, J. van der Zee, S. Gazzina, P. Caroppo, E. Rubino M.A, F. D’Agata, I. Le Ber, I. Santana, G. Cunha, M.R. Almeida, C. Boutoleau-Bretonnière, D. Hannequin, D. Wallon, I. Rainero, D. Galimberti, C.V. Broeckhoven, M.A. Pastor and P. Pastor, Neuroimaging Correlates of Frontotemporal Dementia Associated with SQSTM1 Mutations (1) 303–313
Lundberg, C., see Lovas, J. (2) 631–638
Lunet, N., see Moreira, A. (1) 85–93
Luo, X., see Neugroschl, J. (1) 69–72
Lutsey, P.L., see González, H.M. (3) 955–965
Luz, I., see Salomon-Zimri, S. (4) 1443–1458
Ly, H., see Verma, N. (1) 259–272
Ly, S., see Perkins, M. (1) 95–106
Lynn, B.C., see Lovell, M.A. (1) 273–287
Ma, M., see Uekawa, K. (1) 127–133
Machulda, M.M., see Krell-Roesch, J. (4) 1609–1616
Maeda, M., see Ueda, Y. (1) 315–325
Maioli, S., see Tajeddinn, W. (1) 349–361
Malek-Ahmadi, M., S.E. Perez, K. Chen and E.J. Mufson, Neuritic and Diffuse Plaque Associations with Memory in Non-Cognitively Impaired Elderly (4) 1641–1652
Maliszewska-Cyna, E., K. Xhima and I. Aubert, A Comparative Study Evaluating the Impact of Physical Exercise on Disease Progression in a Mouse Model of Alzheimer’s Disease (1) 243–257
Manera, V., see Ben-Sadoun, G. (4) 1299–1314
Manera, V., see David, R. (4) 1365–1373
Manes, F., see Pietto, M. (4) 1325–1340
Manzanares, J., see Campanari, M.-L. (3) 831–841
Manzanares-Sánchez, S., see Marín-Muñoz, J. (1) 73–78
Marín-Muñoz, J., M.F. Noguera-Perea, E. Gómez-Tortosa, D. López-Motos, M. Antequera-Torres, B. Martínez-Herrada, S. Manzanares-Sánchez, L. Vivancos-Moreau, A. Legaz-García, A. Rábano-Gutiérrez del Arroyo and C. Antúnez-Almagro, Novel Mutation (Gly212Val) in the PS2 Gene Associated with Early-Onset Familial Alzheimer’s Disease (1) 73–78
Marino, S., see Naro, A. (4) 1375–1388
Marra, A., see Naro, A. (4) 1375–1388
Marseglia, A., L. Fratiglioni, E.J. Laukka, G. Santoni, N.L. Pedersen, L. Bäckman and W. Xu, Early Cognitive Deficits in Type 2 Diabetes: A Population-Based Study (3) 1069–1078
Marshall, G.A., see Hsu, D.C. (3) 1097–1105
Martin, J.-J., see Vermeiren, Y. (3) 1079–1096
Martínez-Herrada, B., see Marín-Muñoz, J. (1) 73–78
Martínez-Pinilla, E., see del Valle, E. (2) 639–650
Martinez-Ramirez, S., see Wilker, E.H. (4) 1315–1323
Martiskainen, M., see Skrobot, O.A. (3) 981–989
Matrone, C., see Jakobsen, J.E. (4) 1617–1630
Matsuda, S., see Gao, H.-l. (3) 1173–1192
Matysiak, W., see Mohseni, H.K. (3) 933–942
Mauroo, K., see Vanderstichele, H.M.J. (3) 1121–1132
Maury, F., see Chouraki, V. (3) 921–932
Mayeux, R., see Chouraki, V. (3) 921–932
Mazzanti, M., see Stravalaci, M. (4) 1485–1497
McKee, A.C., see Bangen, K.J. (4) 1553–1562
McKnight, A.J., see Skrobot, O.A. (3) 981–989
Meckel, J.P., see Perkins, M. (1) 95–106
Mecocci, P., see Skrobot, O.A. (3) 981–989
Medvinskaya, N., see Bobkova, N. (1) 289–301
Melnikova, M., see Jakobsen, J.E. (4) 1617–1630
Mendez, M.F., see Paholpak, P. (1) 327–335
Merino-Zamorano, C., S. Fernández-de Retana, A. Montañola, A. Batlle, J. Saint-Pol, C. Mysiorek, F. Gosselet, J. Montaner and M. Hernández-Guillamon, Modulation of Amyloid-β1-40 Transport by ApoA1 and ApoJ Across an in vitro Model of the Blood-Brain Barrier (2) 677–691
Michaelson, D.M., see Salomon-Zimri, S. (4) 1443–1458
Michikawa, M., see Abdullah, M. (4) 1433–1441
Mielke, M.M., see Kantarci, K. (2) 547–556
Mielke, M.M., see Krell-Roesch, J. (4) 1609–1616
Mielke, M.M., see Wennberg, A.M.V. (2) 573–581
Migliore, L., see Grossi, E. (4) 1517–1522
Miklossy, J., Bacterial Amyloid and DNA are Important Constituents of Senile Plaques: Further Evidence of the Spirochetal and Biofilm Nature of Senile Plaques (4) 1459–1473
Milić, A.P., see Mohseni, H.K. (3) 933–942
Miller, V.M., see Kantarci, K. (2) 547–556
Millet, P., see Landel, V. (2) 419–444
Milovanovic, M., see Tajeddinn, W. (2) 621–630
Minkova, L., see Peter, J. (3) 991–1001
Minthon, L., see Andersson, C.-H. (4) 1353–1363
Miraglia, F., see Rossini, P.M. (4) 1389–1393
Mirza, S.S., see Araújo, L.F. (2) 451–461
Mitnitski, A., see Armstrong, J.J. (3) 1003–1013
Mittleman, M.A., see Wilker, E.H. (4) 1315–1323
Mohamed, L.A., see Qosa, H. (4) 1499–1516
Mohseni, H.K., D. Cowan, D.R. Chettle, A.P. Milić, N. Priest, W. Matysiak, J. Atanackovic, S.H. Byun and W.V. Prestwich, A Pilot Study Measuring Aluminum in Bone in Alzheimer’s Disease and control Subjects Using in vivo Neutron Activation Analysis (3) 933–942
Möller, C., see Vijverberg, E.G.B. (4) 1287–1297
Montaner, J., see Merino-Zamorano, C. (2) 677–691
Montañola, A., see Merino-Zamorano, C. (2) 677–691
Mook-Jung, I., see Kang, S. (4) 1563–1576
Moon, S.W., see Suh, S.W. (2) 731–741
Moreira, A., M.J. Diógenes, A. de Mendonça, N. Lunet and H. Barros, Chocolate Consumption is Associated with a Lower Risk of Cognitive Decline (1) 85–93
Morello, M., see Landel, V. (2) 419–444
Morihara, R., see Zhai, Y. (3) 893–905
Mormino, E.C., see Hsu, D.C. (3) 1097–1105
Mosley, T.H., see González, H.M. (3) 955–965
Mostofsky, E., see Wilker, E.H. (4) 1315–1323
Mowrey, W.B., R.B. Lipton, M.J. Katz, W.S. Ramratan, D.A. Loewenstein, M.E. Zimmerman and H. Buschke, Memory Binding Test Predicts Incident Amnestic Mild Cognitive Impairment (4) 1585–1595
Mufson, E.J., see Malek-Ahmadi, M. (4) 1641–1652
Mukherjee, S., see Chouraki, V. (3) 921–932
Munafò, M., see Skrobot, O.A. (3) 981–989
Murabito, J.M., see Camargo, E.C. (4) 1597–1608
Murgas, P., see Eugenín, J. (3) 857–873
Murphy, M.P., see Lovell, M.A. (1) 273–287
Muscarà, N., see Naro, A. (4) 1375–1388
Muti, E., see Venturelli, M. (4) 1631–1640
Mysiorek, C., see Merino-Zamorano, C. (2) 677–691
Na, D.L., see Kang, S. (4) 1563–1576
Na, D.L., see Roh, H.W. (2) 463–473
Nabeka, H., see Gao, H.-l. (3) 1173–1192
Nagely, A.C., see Vidoni, E.D. (1) 161–170
Naglie, G., see Hird, M.A. (2) 713–729
Najem, D., see Bamji-Mirza, M. (3) 875–892
Nakagata, N., see Uekawa, K. (1) 127–133
Nakagawa, T., see Uekawa, K. (1) 127–133
Nakamura, N., see Yamasaki, T. (2) 661–676
Nakano, Y., see Zhai, Y. (3) 893–905
Nardo, E., see Biella, G. (3) 1193–1207
Naro, A., F. Corallo, S. De Salvo, A. Marra, G. Di Lorenzo, N. Muscarà, M. Russo, S. Marino, R. De Luca, P. Bramanti and R.S. Calabrò, Promising Role of Neuromodulation in Predicting the Progression of Mild Cognitive Impairment to Dementia (4) 1375–1388
Nation, D.A., see Bangen, K.J. (4) 1553–1562
Navarrete, F., see Campanari, M.-L. (3) 831–841
Navarro, A., see del Valle, E. (2) 639–650
Nekrasov, P., see Bobkova, N. (1) 289–301
Nesterova, I., see Bobkova, N. (1) 289–301
Neugroschl, J., M. Sewell, A. De La Fuente, M. Umpierre, X. Luo and M. Sano, Attitudes and Perceptions of Research in Aging and Dementia in an Urban Minority Population (1) 69–72
Newberg, A., see Amen, D.G. (1) 237–241
Ni, M., see Wang, J. (3) 907–919
Nicholas, C.L., see Cavuoto, M.G. (3) 943–953
Nielsen, A.L., see Jakobsen, J.E. (4) 1617–1630
Niessen, W.J., see Araújo, L.F. (2) 451–461
Nilsson, S., see Andersson, C.-H. (4) 1353–1363
Nissen, C., see Peter, J. (3) 991–1001
Noguera-Perea, M.F., see Marín-Muñoz, J. (1) 73–78
Noh, J.S., see Roh, H.W. (2) 463–473
Normann, C., see Peter, J. (3) 991–1001
Norris, C.M., see Lovell, M.A. (1) 273–287
Nunome, M., see Abdullah, M. (4) 1433–1441
O’Regan, C., see Feeney, J. (3) 1107–1114
Oboshi, Y., M. Kikuchi, T. Terada, E. Yoshikawa, T. Bunai and Y. Ouchi, Alterations in Phase-Related Prefrontal Activation During Cognitive Tasks and Nicotinic α4β2 Receptor Availability in Alzheimer’s Disease (3) 817–830
Offen, D., see Salomon-Zimri, S. (4) 1443–1458
Ogueta, S., see Allué, J.A. (3) 773–785
Ohta, Y., see Zhai, Y. (3) 893–905
Ohyagi, Y., see Yamasaki, T. (2) 661–676
Okun, I., see Ivachtchenko, A.V. (2) 583–620
Omalu, B., see Amen, D.G. (1) 237–241
Ong, B., see Cavuoto, M.G. (3) 943–953
Oren, N., see Yogev-Seligmann, G. (2) 517–533
Ortega-Cubero, S., see Luis, E. (1) 303–313
Ortiz, A., see Luis, E. (1) 303–313
Otahal, P., see Callisaya, M.L. (3) 1043–1052
Ouchi, Y., see Oboshi, Y. (3) 817–830
Pahnke, J., see Hofrichter, J. (3) 967–980
Paholpak, P., L. Li-Jung, D.R. Carr, E. Jimenez, R.J. Barrows, V. Sabodash and M.F. Mendez, Prolonged Visual Facial Grasp in Frontotemporal Dementia (1) 327–335
Pai, M.-C., see Tsai, C.-L. (1) 143–159
Pan, S., see Zhou, X. (3) 843–855
Panza, F., see Di Carlo, A. (2) 505–515
Panza, F., see Skrobot, O.A. (3) 981–989
Paquet, C., see Dumurgier, J. (4) 1411–1418
Park, J.H., see Suh, S.W. (2) 731–741
Park, J.Y., see Suh, S.W. (2) 731–741
Parra, M.A., see Pietto, M. (4) 1325–1340
Parrado-Fernández, C., see Tajeddinn, W. (1) 349–361
Pascual-Lucas, M., see Allué, J.A. (3) 773–785
Passmore, P.A., see Skrobot, O.A. (3) 981–989
Pastor, M.A., see Luis, E. (1) 303–313
Pastor, P., see Luis, E. (1) 303–313
Pedersen, N.L., see Marseglia, A. (3) 1069–1078
Pemberton, H., see Brodtmann, A. (1) 79–83
Penke, B., see Kasza, Á. (2) 557–571
Penninkilampi, R., H.M. Brothers and G.D. Eslick, Pharmacological Agents Targeting γ -Secretase Increase Risk of Cancer and Cognitive Decline in Alzheimer’s Disease Patients: A Systematic Review and Meta-Analysis (4) 1395–1404
Peoples, R.W., see Peters, C. (1) 197–207
Perales, J., O. Turró-Garriga, J. Gascón-Bayarri, R. Reñé-Ramírez and J.L. Conde-Sala, The Longitudinal Association Between a Discrepancy Measure of Anosognosia in Patients with Dementia, Caregiver Burden and Depression (3) 1133–1143
Perez, S.E., see Malek-Ahmadi, M. (4) 1641–1652
Pérez-Grijalba, V., see Allué, J.A. (3) 773–785
Perkins, M., A.B. Wolf, B. Chavira, D. Shonebarger, J.P. Meckel, L. Leung, L. Ballina, S. Ly, A. Saini, T.B. Jones, J. Vallejo, G. Jentarra and J. Valla, Altered Energy Metabolism Pathways in the Posterior Cingulate in Young Adult Apolipoprotein E e4 Carriers (1) 95–106
Persson, T., see Tajeddinn, W. (1) 349–361
Pesini, P., see Allué, J.A. (3) 773–785
Pessi, T., see Skrobot, O.A. (3) 981–989
Peter, J., J. Lahr, L. Minkova, E. Lauer, M.J. Grothe, S. Teipel, L. Köstering, C.P. Kaller, B. Heimbach, M. Hüll, C. Normann, C. Nissen, J. Reis and S. Klöppel, Contribution of the Cholinergic System to Verbal Memory Performance in Mild Cognitive Impairment (3) 991–1001
Peters, A., see Vijverberg, E.G.B. (4) 1287–1297
Peters, C., F.J. Sepúlveda, E.J. Fernández-Pérez, R.W. Peoples and L.G. Aguayo, The Level of NMDA Receptor in the Membrane Modulates Amyloid-β Association and Perforation (1) 197–207
Petersen, R.C., see Krell-Roesch, J. (4) 1609–1616
Petersen, R.C., see Wennberg, A.M.V. (2) 573–581
Peuckert, C., see Farnsworth, B. (1) 209–219
Pickett, E.K., R.M. Koffie, S. Wegmann, C.M. Henstridge, A.G. Herrmann, M. Colom-Cadena, A. Lleo, K.R. Kay, M. Vaught, R. Soberman, D.M. Walsh, B.T. Hyman and T.L. Spires-Jones, Non-Fibrillar Oligomeric Amyloid-β within Synapses (3) 787–800
Pietto, M., M.A. Parra, N. Trujillo, F. Flores, A.M. García, J. Bustin, P. Richly, F. Manes, F. Lopera, A. Ibáñez and S. Baez, Behavioral and Electrophysiological Correlates of Memory Binding Deficits in Patients at Different Risk Levels for Alzheimer’s Disease (4) 1325–1340
Piguet, O., see Dermody, N. (3) 801–816
Piguet, O., see Langenhove, T.V. (3) 1033–1042
Pijnenburg, Y.A.L., see Staekenborg, S.S. (1) 135–142
Pijnenburg, Y.A.L., see Vijverberg, E.G.B. (4) 1287–1297
Pijnenburg, Y.A.L., see Willemse, E.A.J. (1) 107–116
Pike, K.E., see Cavuoto, M.G. (3) 943–953
Pink, A., see Krell-Roesch, J. (4) 1609–1616
Pires, M.M., see Taipa, R. (2) 403–417
Pirzada, A., see González, H.M. (3) 955–965
Pizzi, E., see Stravalaci, M. (4) 1485–1497
Pradier, C., see David, R. (4) 1365–1373
Praticò, D., see Di Meco, A. (2) 367–372
Prestwich, W.V., see Mohseni, H.K. (3) 933–942
Pretorius, E., J. Bester and D.B. Kell, A Bacterial Component to Alzheimer’s-Type Dementia Seen via a Systems Biology Approach that Links Iron Dysregulation and Inflammagen Shedding to Disease (4) 1237–1256
Prevot, M., see Dumurgier, J. (4) 1411–1418
Price, D., see Happich, M. (1) 171–183
Priest, N., see Mohseni, H.K. (3) 933–942
Prins, N.D., see Vijverberg, E.G.B. (4) 1287–1297
Prodromou, C., see Kasza, Á. (2) 557–571
Protein Tau (1) 1–14
Qiao, S., see Wang, J. (3) 907–919
Qosa, H., L.A. Mohamed, S.B. Al Rihani, Y.S. Batarseh, Q.-V. Duong, J.N. Keller and A. Kaddoumi, High-Throughput Screening for Identification of Blood-Brain Barrier Integrity Enhancers: A Drug Repurposing Opportunity to Rectify Vascular Amyloid Toxicity (4) 1499–1516
Quenon, L., see Hanseeuw, B. (2) 651–660
Rábano-Gutiérrez del Arroyo, A., see Marín-Muñoz, J. (1) 73–78
Raghavendra, C., see Amen, D.G. (1) 237–241
Rainero, I., see Luis, E. (1) 303–313
Raje, S., see Russu, A. (2) 535–546
Raji, C.A., see Amen, D.G. (1) 237–241
Ramratan, W.S., see Mowrey, W.B. (4) 1585–1595
Reed, C., see Happich, M. (1) 171–183
Reis, J., see Peter, J. (3) 991–1001
Reitz, C., see Chouraki, V. (3) 921–932
Religa, D., see Lovas, J. (2) 631–638
Reñé-Ramírez, R., see Perales, J. (3) 1133–1143
Rentz, D.M., see Hsu, D.C. (3) 1097–1105
Richly, P., see Pietto, M. (4) 1325–1340
Robberecht, C., see De Vos, A. (4) 1523–1538
Robert, P., see Ben-Sadoun, G. (4) 1299–1314
Robert, P., see David, R. (4) 1365–1373
Roberts, R.O., see Krell-Roesch, J. (4) 1609–1616
Roberts, R.O., see Wennberg, A.M.V. (2) 573–581
Rocca, W.A., see Kantarci, K. (2) 547–556
Rocha, N.P., see Salem, H. (3) 1209–1230
Rockwood, K., see Armstrong, J.J. (3) 1003–1013
Rodríguez, C.J., see González, H.M. (3) 955–965
Rogaeva, E., see Bamji-Mirza, M. (3) 875–892
Roh, H.W., C.H. Hong, Y. Lee, K.S. Lee, K.J. Chang, D.R. Kang, J.-D. Lee, S.H. Choi, S.Y. Kim, D.L. Na, S.W. Seo, D.K. Kim, J.H. Back, Y.K. Chung, K.Y. Lim, J.S. Noh and S.J. Son, Clinical Conversion or Reversion of Mild Cognitive Impairment in Community versus Hospital Based Studies: GDEMCIS (Gwangju Dementia and Mild Cognitive Impairment Study) and CREDOS (Clinical Research Center for Dementia of South Korea) (2) 463–473
Rong, P., see Li, X. (4) 1577–1584
Rongve, A., see Brønnick, K. (4) 1277–1285
Rosenhall, U., see Idrizbegovic, E. (4) 1405–1410
Rossi, A., see Stravalaci, M. (4) 1485–1497
Rossini, P.M., R. Di Iorio, G. Granata, F. Miraglia and F. Vecchio, From Mild Cognitive Impairment to Alzheimer’s Disease: A New Perspective in the “Land” of Human Brain Reactivity and Connectivity (4) 1389–1393
Rubino M.A, E., see Luis, E. (1) 303–313
Ruider, H., see Krell-Roesch, J. (4) 1609–1616
Rundek, T., see González, H.M. (3) 955–965
Russo, M., see Naro, A. (4) 1375–1388
Russu, A., M.N. Samtani, S. Xu, O.J. Adedokun, M. Lu, K. Ito, B. Corrigan, S. Raje, E. Liu, H.R. Brashear, S. Styren and C. Hu, Biomarker Exposure-Response Analysis in Mild-To-Moderate Alzheimer’s Disease Trials of Bapineuzumab (2) 535–546
Ryu, S.-H., see Suh, S.W. (2) 731–741
Sabodash, V., see Paholpak, P. (1) 327–335
Sacco, G., see Ben-Sadoun, G. (4) 1299–1314
Sáez-Valero, J., see Campanari, M.-L. (3) 831–841
Saini, A., see Perkins, M. (1) 95–106
Saint-Pol, J., see Merino-Zamorano, C. (2) 677–691
Sakuma, H., see Ueda, Y. (1) 315–325
Saladie, D.G., see Bolívar, J.C.C. (2) 705–712
Salem, H., N.P. Rocha, G.D. Colpo and A.L. Teixeira, Moving from the Dish to the Clinical Practice: A Decade of Lessons and Perspectives from the Pre-Clinical and Clinical Stem Cell Studies for Alzheimer’s Disease (3) 1209–1230
Salmona, M., see Stravalaci, M. (4) 1485–1497
Salomon-Zimri, S., M.J. Glat, Y. Barhum, I. Luz, A. Boehm-Cagan, O. Liraz, T. Ben-Zur, D. Offen and D.M. Michaelson, Reversal of ApoE4-Driven Brain Pathology by Vascular Endothelial Growth Factor Treatment (4) 1443–1458
Samokhin, A., see Bobkova, N. (1) 289–301
Samtani, M.N., see Russu, A. (2) 535–546
Sano, M., see Neugroschl, J. (1) 69–72
Santana, I., see Luis, E. (1) 303–313
Sántha, M., see Kasza, Á. (2) 557–571
Santoni, G., see Marseglia, A. (3) 1069–1078
Sarasa, L., see Allué, J.A. (3) 773–785
Sarasa, M., see Allué, J.A. (3) 773–785
Sassi, C., R. Capozzo, R. Gibbs, C. Crews, C. Zecca, S. Arcuti, M. Copetti, M.R. Barulli, V. Brescia, A.B. Singleton and G. Logroscino, A Novel Splice-Acceptor Site Mutation in GRN (c.709-2 A>T) Causes Frontotemporal Dementia Spectrum in a Large Family from Southern Italy (2) 475–485
Satoh, M., see Ueda, Y. (1) 315–325
Savva, G.M., see Feeney, J. (3) 1107–1114
Scafato, E., see Di Carlo, A. (2) 505–515
Scarpini, E., see Galimberti, D. (2) 445–449
Scheltens, P., see Staekenborg, S.S. (1) 135–142
Scheltens, P., see Vijverberg, E.G.B. (4) 1287–1297
Schmidt, M., see Jakobsen, J.E. (4) 1617–1630
Schultz, A.P., see Hsu, D.C. (3) 1097–1105
Schumacher, T., see Hofrichter, J. (3) 967–980
Schuster, J. and S.A. Funke, Methods for the Specific Detection and Quantitation of Amyloid-β Oligomers in Cerebrospinal Fluid (1) 53–67
Schwartz, J., see Wilker, E.H. (4) 1315–1323
Schweizer, T.A., see Hird, M.A. (2) 713–729
Sciver, A.V., see Vidoni, E.D. (1) 161–170
Sengpiel, F., see Bobkova, N. (1) 289–301
Senjem, M.L., see Kantarci, K. (2) 547–556
Senju, S., see Uekawa, K. (1) 127–133
Seo, J., see Suh, S.W. (2) 731–741
Seo, S.W., see Kang, S. (4) 1563–1576
Seo, S.W., see Roh, H.W. (2) 463–473
Sepúlveda, F.J., see Peters, C. (1) 197–207
Sergio, L.E., see Hawkins, K.M. (3) 1161–1172
Seripa, D., see Skrobot, O.A. (3) 981–989
Seshadri, S., see Bangen, K.J. (4) 1553–1562
Seshadri, S., see Camargo, E.C. (4) 1597–1608
Seshadri, S., see Chouraki, V. (3) 921–932
Sewell, M., see Neugroschl, J. (1) 69–72
Shahnaz, T., see Tajeddinn, W. (2) 621–630
Shang, J., see Zhai, Y. (3) 893–905
Shen, L., see Han, B. (4) 1539–1552
Shimokawa, T., see Gao, H.-l. (3) 1173–1192
Shonebarger, D., see Perkins, M. (1) 95–106
Shu, N., see Zhang, J. (1) 185–195
Shuster, L.T., see Kantarci, K. (2) 547–556
Sieben, A., see Vermeiren, Y. (3) 1079–1096
Singleton, A.B., see Sassi, C. (2) 475–485
Skoog, I., see Andersson, C.-H. (4) 1353–1363
Skrobot, O.A., A.J. McKnight, P.A. Passmore, D. Seripa, P. Mecocci, F. Panza, R. Kalaria, G. Wilcock, M. Munafò, T. Erkinjuntti, P. Karhunen, T. Pessi, M. Martiskainen, S. Love, the Genetic and Environmental Risk for Alzheimer’s disease Consortium (GERAD1) and P.G. Kehoe, A Validation Study of Vascular Cognitive Impairment Genetics Meta-Analysis Findings in an Independent Collaborative Cohort (3) 981–989
Soberman, R., see Pickett, E.K. (3) 787–800
Solfrizzi, V., see Di Carlo, A. (2) 505–515
Sollima, A., see Venturelli, M. (4) 1631–1640
Son, S.J., see Roh, H.W. (2) 463–473
Sousa, A.L., see Taipa, R. (2) 403–417
Sousa, N., see Taipa, R. (2) 403–417
Sperling, R.A., see Hsu, D.C. (3) 1097–1105
Spires-Jones, T.L., see Pickett, E.K. (3) 787–800
Srikanth, V.K., see Callisaya, M.L. (3) 1043–1052
Staekenborg, S.S., Y.A.L. Pijnenburg, A.W. Lemstra, P. Scheltens and W.M. vd Flier, Dementia and Rapid Mortality: Who is at Risk? (1) 135–142
Stek, M.L., see Vijverberg, E.G.B. (4) 1287–1297
Stoccoro, A., see Grossi, E. (4) 1517–1522
Stokin, G.B., see Krell-Roesch, J. (4) 1609–1616
Stoops, E., see Vanderstichele, H.M.J. (3) 1121–1132
Stravalaci, M., L. Tapella, M. Beeg, A. Rossi, P. Joshi, E. Pizzi, M. Mazzanti, C. Balducci, G. Forloni, E. Biasini, M. Salmona, L. Diomede, R. Chiesa and M. Gobbi, The Anti-Prion Antibody 15B3 Detects Toxic Amyloid-β Oligomers (4) 1485–1497
Struyfs, H., see De Vos, A. (4) 1523–1538
Stupak, J., see Bamji-Mirza, M. (3) 875–892
Styren, S., see Russu, A. (2) 535–546
Suh, S.W., J.W. Han, J.Y. Park, J.W. Hong, K. Kim, T. Kim, K.H. Lee, G. Han, H. Jeong, J. Seo, T.H. Kim, D.Y. Lee, D.W. Lee, S.-H. Ryu, S.-G. Kim, J.C. Youn, J.H. Jhoo, J.L. Kim, S.B. Lee, J.J. Lee, K.P. Kwak, B.-J. Kim, S.W. Moon, J.H. Park and K.W. Kim, Impacts of Illiteracy on the Risk of Dementia: A Global Health Perspective (2) 731–741
Sun, Z., see Zhai, Y. (3) 893–905
Szalárdy, L., D. Zádori, P. Klivényi and L. Vécsei, The Role of Cerebrospinal Fluid Biomarkers in the Evolution of Diagnostic Criteria in Alzheimer’s Disease: Shortcomings in Prodromal Diagnosis (2) 373–392
Tabei, K.-i., see Ueda, Y. (1) 315–325
Taipa, R., A.L. Sousa, M.M. Pires and N. Sousa, Does the Interplay Between Aging and Neuroinflammation Modulate Alzheimer’s Disease Clinical Phenotypes? A Clinico-Pathological Perspective (2) 403–417
Tajeddinn, W., S.-M. Fereshtehnejad, M.S. Ahmed, T. Yoshitake, J. Kehr, T. Shahnaz, M. Milovanovic, H. Behbahani, K. Höglund, B. Winblad, A. Cedazo-Minguez, V. Jelic, P. Järemo and D. Aarsland, Association of Platelet Serotonin Levels in Alzheimer’s Disease with Clinical and Cerebrospinal Fluid Markers (2) 621–630
Tajeddinn, W., T. Persson, J. Calvo-Garrido, M.S. Ahmed, S. Maioli, S. Vijayaraghavan, M.S. Kazokoglu, C. Parrado-Fernández, T. Yoshitake, J. Kehr, P. Francis, B. Winblad, K. Höglund, A. Cedazo-Minguez and D. Aarsland, Pharmacological Modulations of the Serotonergic System in a Cell-Model of Familial Alzheimer’s Disease (1) 349–361
Takase, H., see Abdullah, M. (4) 1433–1441
Tan, Z.S., see Camargo, E.C. (4) 1597–1608
Tanaka, E., see Yamasaki, T. (2) 661–676
Tang, W., J. Cheng, Z.-Y. Wang, K.-Y. Chen, Z.-M. Han, Q.-H. Wang and Y.-Y. Yao, The Synergistic Roles of the Chronic Prenatal and Offspring Stress Exposures in Impairing Offspring Learning and Memory (1) 221–236
Tannorella, P., see Grossi, E. (4) 1517–1522
Tapella, L., see Stravalaci, M. (4) 1485–1497
Tarraf, W., see González, H.M. (3) 955–965
Tatarnikova, O., see Bobkova, N. (1) 289–301
Tat-Wei Tan, D., see Lin, C.-Y. (3) 1053–1067
Teipel, S., see Peter, J. (3) 991–1001
Teixeira, A.L., see Salem, H. (3) 1209–1230
Terada, T., see Oboshi, Y. (3) 817–830
Teunissen, C.E., see Willemse, E.A.J. (1) 107–116
Tiemeier, H., see Araújo, L.F. (2) 451–461
Tifratene, K., see David, R. (4) 1365–1373
Tobimatsu, S., see Yamasaki, T. (2) 661–676
Tolivia, J., see del Valle, E. (2) 639–650
Tomimoto, H., see Ueda, Y. (1) 315–325
Torices, S., see del Valle, E. (2) 639–650
Török, Z., see Kasza, Á. (2) 557–571
Tosakulwong, N., see Kantarci, K. (2) 547–556
Trojano, L. and G. Gainotti, Drawing Disorders in Alzheimer’s Disease and Other Forms of Dementia (1) 31–52
Trujillo, N., see Pietto, M. (4) 1325–1340
Tsai, C.-L., M.-C. Pai, J. Ukropec and B. Ukropcová, The Role of Physical Fitness in the Neurocognitive Performance of Task Switching in Older Persons with Mild Cognitive Impairment (1) 143–159
Tu, P.-h., see Lin, C.-Y. (3) 1053–1067
Turró-Garriga, O., see Garre-Olmo, J. (4) 1341–1351
Turró-Garriga, O., see Perales, J. (3) 1133–1143
Twu, W.-I., see Lin, C.-Y. (3) 1053–1067
Tzourio, C., see Dumurgier, J. (4) 1411–1418
Ueda, Y., M. Satoh, K.-i. Tabei, H. Kida, Y. Ii, M. Asahi, M. Maeda, H. Sakuma and H. Tomimoto, Neuropsychological Features of Microbleeds and Cortical Microinfarct Detected by High Resolution Magnetic Resonance Imaging (1) 315–325
Uekawa, K., Y. Hasegawa, S. Senju, N. Nakagata, M. Ma, T. Nakagawa, N. Koibuchi and S. Kim-Mitsuyama, Intracerebroventricular Infusion of Angiotensin-(1–7) Ameliorates Cognitive Impairment and Memory Dysfunction in a Mouse Model of Alzheimer’s Disease (1) 127–133
Uitterlinden, A.G., see Chouraki, V. (3) 921–932
Ukropcová, B., see Tsai, C.-L. (1) 143–159
Ukropec, J., see Tsai, C.-L. (1) 143–159
Umpierre, M., see Neugroschl, J. (1) 69–72
Uphoff, E., see Vidoni, E.D. (1) 161–170
Vaartjes, I., see van de Vorst, I.E. (1) 117–125
Valla, J., see Perkins, M. (1) 95–106
Vallejo, J., see Perkins, M. (1) 95–106
van Berckel, B.N.M., see Vijverberg, E.G.B. (4) 1287–1297
Van Broeckhoven, C., see De Vos, A. (4) 1523–1538
Van Dam, D., see Vermeiren, Y. (3) 1079–1096
van de Vorst, I.E., H.L. Koek, M.L. Bots and I. Vaartjes, Evaluation of Underlying Causes of Death in Patients with Dementia to Support Targeted Advance Care Planning (1) 117–125
van der Flier, W.M., see Willemse, E.A.J. (1) 107–116
van der Lee, S.J., see Chouraki, V. (3) 921–932
van der Lugt, A., see Araújo, L.F. (2) 451–461
van der Zee, J., see Luis, E. (1) 303–313
van Duijn, C., see Chouraki, V. (3) 921–932
Vanderstichele, H.M.J., S. Janelidze, L. Demeyer, E. Coart, E. Stoops, V. Herbst, K. Mauroo, B. Brix and O. Hansson, Optimized Standard Operating Procedures for the Analysis of Cerebrospinal Fluid Aβ42 and the Ratios of Aβ Isoforms Using Low Protein Binding Tubes (3) 1121–1132
Vanmechelen, E., see De Vos, A. (4) 1523–1538
Vardarajan, B., see Chouraki, V. (3) 921–932
Varley, R.A., see Zimmerer, V.C. (3) 1145–1160
Vaught, M., see Pickett, E.K. (3) 787–800
vd Flier, W.M., see Staekenborg, S.S. (1) 135–142
Vecchio, F., see Rossini, P.M. (4) 1389–1393
Vecchiola, A., see Eugenín, J. (3) 857–873
Vécsei, L., see Szalárdy, L. (2) 373–392
Venturelli, M., A. Sollima, E. Cè, E. Limonta, A.V. Bisconti, A. Brasioli, E. Muti and F. Esposito, Effectiveness of Exercise- and Cognitive-Based Treatments on Salivary Cortisol Levels and Sundowning Syndrome Symptoms in Patients with Alzheimer’s Disease (4) 1631–1640
Verghese, J., see Callisaya, M.L. (3) 1043–1052
Verma, N., H. Ly, M. Liu, J. Chen, H. Zhu, M. Chow, L.B. Hersh and F. Despa, Intraneuronal Amylin Deposition, Peroxidative Membrane Injury and Increased IL-1β Synthesis in Brains of Alzheimer’s Disease Patients with Type-2 Diabetes and in Diabetic HIP Rats (1) 259–272
Vermeiren, Y., J. Janssens, T. Aerts, J.-J. Martin, A. Sieben, D. Van Dam and P.P. De Deyn, Brain Serotonergic and Noradrenergic Deficiencies in Behavioral Variant Frontotemporal Dementia Compared to Early-Onset Alzheimer’s Disease (3) 1079–1096
Vernooij, M.W., see Akoudad, S. (2) 497–503
Vernooij, M.W., see Araújo, L.F. (2) 451–461
Vidoni, E.D., A.S. Watts, J.M. Burns, C.S. Greer, R.S. Graves, A.V. Sciver, J.R. Black, S.K. Cooper, A.C. Nagely, E. Uphoff, J.M. Volmer and N.A. Bieberle, Feasibility of a Memory Clinic-Based Physical Activity Prescription Program (1) 161–170
Vigh, L., see Kasza, Á. (2) 557–571
Vijayaraghavan, S., see Tajeddinn, W. (1) 349–361
Vijverberg, E.G.B., M.P. Wattjes, A. Dols, W.A. Krudop, C. Möller, A. Peters, C.J. Kerssens, F. Gossink, N.D. Prins, M.L. Stek, P. Scheltens, B.N.M. van Berckel, F. Barkhof and Y.A.L. Pijnenburg, Diagnostic Accuracy of MRI and Additional [18F]FDG-PET for Behavioral Variant Frontotemporal Dementia in Patients with Late Onset Behavioral Changes (4) 1287–1297
Viswanathan, A., see Wilker, E.H. (4) 1315–1323
Vivancos-Moreau, L., see Marín-Muñoz, J. (1) 73–78
Vogel, A.P., see Brodtmann, A. (1) 79–83
Volmer, J.M., see Vidoni, E.D. (1) 161–170
Volpina, O., see Bobkova, N. (1) 289–301
von Bernhardi, R., see Eugenín, J. (3) 857–873
Vorobyov, V., see Bobkova, N. (1) 289–301
Walbroel, B., see Hofrichter, J. (3) 967–980
Walker, D., see Bamji-Mirza, M. (3) 875–892
Wallin, A., see Andersson, C.-H. (4) 1353–1363
Wallon, D., see Luis, E. (1) 303–313
Walsh, D.M., see Pickett, E.K. (3) 787–800
Wang, H., see Han, B. (4) 1539–1552
Wang, J., F. Ye, X. Cheng, X. Zhang, F. Liu, G. Liu, M. Ni, S. Qiao, W. Zhou and Y. Zhang, The Effects of LW-AFC on Intestinal Microbiome in Senescence-Accelerated Mouse Prone 8 Strain, a Mouse Model of Alzheimer’s Disease (3) 907–919
Wang, J., see Han, B. (4) 1539–1552
Wang, M., see Han, B. (4) 1539–1552
Wang, Q.-H., see Tang, W. (1) 221–236
Wang, Y., see Han, B. (4) 1539–1552
Wang, Y., see Zhang, J. (1) 185–195
Wang, Z.-Y., see Gao, H.-l. (3) 1173–1192
Wang, Z.-Y., see Tang, W. (1) 221–236
Wattjes, M.P., see Vijverberg, E.G.B. (4) 1287–1297
Watts, A.S., see Vidoni, E.D. (1) 161–170
Wegmann, S., see Pickett, E.K. (3) 787–800
Wei, J., see Deng, Y. (4) 1419–1432
Weinstein, G., see Camargo, E.C. (4) 1597–1608
Wennberg, A.M.V., D. Gustafson, C.E. Hagen, R.O. Roberts, D. Knopman, C. Jack Jr, R.C. Petersen and M.M. Mielke, Serum Adiponectin Levels, Neuroimaging, and Cognition in the Mayo Clinic Study of Aging (2) 573–581
White, L.R., see Armstrong, J.J. (3) 1003–1013
Wibrow, M., see Zimmerer, V.C. (3) 1145–1160
Wilcock, G., see Skrobot, O.A. (3) 981–989
Wilker, E.H., S. Martinez-Ramirez, I. Kloog, J. Schwartz, E. Mostofsky, P. Koutrakis, M.A. Mittleman and A. Viswanathan, Fine Particulate Matter, Residential Proximity to Major Roads, and Markers of Small Vessel Disease in a Memory Study Population (4) 1315–1323
Willemse, E.A.J., S. Durieux-Lu, W.M. van der Flier, Y.A.L. Pijnenburg, R. de Jonge and C.E. Teunissen, Stability of Progranulin Under Pre-Analytical Conditions in Serum and Cerebrospinal Fluid (1) 107–116
Willeumier, K., see Amen, D.G. (1) 237–241
Winblad, B., see Lovas, J. (2) 631–638
Winblad, B., see Tajeddinn, W. (1) 349–361
Winblad, B., see Tajeddinn, W. (2) 621–630
Wolf, A.B., see Perkins, M. (1) 95–106
Wolf, P.A., see Bangen, K.J. (4) 1553–1562
Wong, S., see Dermody, N. (3) 801–816
Woody, S.K., H. Zhou, S. Ibrahimi, Y. Dong and L. Zhao, Human ApoE e2 Promotes Regulatory Mechanisms of Bioenergetic and Synaptic Function in Female Brain: A Focus on V-type H+-ATPase (3) 1015–1031
Wright, C., see González, H.M. (3) 955–965
Xhima, K., see Maliszewska-Cyna, E. (1) 243–257
Xia, J., see El Gaamouch, F. (1) 15–29
Xiong, Z., see Deng, Y. (4) 1419–1432
Xu, M., see Zhou, X. (3) 843–855
Xu, S., see Russu, A. (2) 535–546
Xu, W., see Marseglia, A. (3) 1069–1078
Yamasaki, T., S. Horie, Y. Ohyagi, E. Tanaka, N. Nakamura, Y. Goto, S. Kanba, J.-i. Kira and S. Tobimatsu, A Potential VEP Biomarker for Mild Cognitive Impairment: Evidence from Selective Visual Deficit of Higher-Level Dorsal Pathway (2) 661–676
Yamashita, T., see Zhai, Y. (3) 893–905
Yan, Z., see Deng, Y. (4) 1419–1432
Yang, Z., see Bamji-Mirza, M. (3) 875–892
Yang, Z., see Li, H. (2) 487–496
Yao, Y.-Y., see Tang, W. (1) 221–236
Ye, F., see Wang, J. (3) 907–919
Yi, E.C., see Kang, S. (4) 1563–1576
Yogev-Seligmann, G., N. Oren, E.L. Ash, T. Hendler, N. Giladi and Y. Lerner, Altered Topology in Information Processing of a Narrated Story in Older Adults with Mild Cognitive Impairment (2) 517–533
Yoshikawa, E., see Oboshi, Y. (3) 817–830
Yoshitake, T., see Tajeddinn, W. (1) 349–361
Yoshitake, T., see Tajeddinn, W. (2) 621–630
Youn, J.C., see Suh, S.W. (2) 731–741
Yu, J., R. Li, Y. Jiang, L.S. Broster and J. Li, Altered Brain Activities Associated with Neural Repetition Effects in Mild Cognitive Impairment Patients (2) 693–704
Yu, L., see Chouraki, V. (3) 921–932
Yu, L., see Han, B. (4) 1539–1552
Zádori, D., see Szalárdy, L. (2) 373–392
Zecca, C., see Sassi, C. (2) 475–485
Zeiler, H.-J., see Kasza, Á. (2) 557–571
Zetterberg, H., see Andersson, C.-H. (4) 1353–1363
Zhai, Y., T. Yamashita, Y. Nakano, Z. Sun, J. Shang, T. Feng, R. Morihara, Y. Fukui, Y. Ohta, N. Hishikawa and K. Abe, Chronic Cerebral Hypoperfusion Accelerates Alzheimer’s Disease Pathology with Cerebrovascular Remodeling in a Novel Mouse Model (3) 893–905
Zhang, J., Z. Liu, Z. Li, Y. Wang, Y. Chen, X. Li, K. Chen, N. Shu and Z. Zhang, Disrupted White Matter Network and Cognitive Decline in Type 2 Diabetes Patients (1) 185–195
Zhang, W., see Bamji-Mirza, M. (3) 875–892
Zhang, X., see Wang, J. (3) 907–919
Zhang, Y., see Wang, J. (3) 907–919
Zhang, Z., see Zhang, J. (1) 185–195
Zhao, L., see Woody, S.K. (3) 1015–1031
Zheng, W., see Li, X. (4) 1577–1584
Zhong, P., see Deng, Y. (4) 1419–1432
Zhou, H., see Woody, S.K. (3) 1015–1031
Zhou, W., see Wang, J. (3) 907–919
Zhou, X., J. Huang, S. Pan, M. Xu, R. He, Z. Ji and Y. Hu, Neurodegeneration-Like Pathological and Behavioral Changes in an AAV9-Mediated p25 Overexpression Mouse Model (3) 843–855
Zhou, Z., see Li, X. (4) 1577–1584
Zhu, H., see Verma, N. (1) 259–272
Zimmerer, V.C., M. Wibrow and R.A. Varley, Formulaic Language in People with Probable Alzheimer’s Disease: A Frequency-Based Approach (3) 1145–1160
Zimmerman, M.E., see Mowrey, W.B. (4) 1585–1595
Zimmermann, B., see Farnsworth, B. (1) 209–219
Zuk, S.M., see Kantarci, K. (2) 547–556
